STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated news page for Bristol-Myers Squibb Co. (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bristol-Myers Squibb Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bristol-Myers Squibb Co.'s position in the market.

News
Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers
Rhea-AI Summary
Bristol Myers Squibb (BMY) announced the presentation of data at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium, highlighting the company’s progress in making long-term survival outcomes a possibility for more patients with genitourinary cancers. The data includes the first presentation of results from the Phase 3 CheckMate -67T trial with a subcutaneous formulation of Opdivo, as well as four-year data from CheckMate -9ER and unprecedented eight-year data from CheckMate -214, confirming durable outcomes with Opdivo-based combinations for patients with advanced renal cell carcinoma. Additionally, the disclosure of clinical outcomes from a Phase 1 trial with BMS-986365 in metastatic castration-resistant prostate cancer showcases potential new options and therapeutic platforms that may transform treatment paradigms across tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.04%
Tags
none
-
News
Healthpeak Properties Enters into a New $236 Million Joint Venture with Breakthrough Properties on the Callan Ridge Lab Campus in Torrey Pines
Rhea-AI Summary
Healthpeak Properties, Inc. (NYSE: PEAK) announced a new strategic joint venture with Breakthrough Properties, selling a 65% interest in its fully leased Callan Ridge lab campus in San Diego. The joint venture values Callan Ridge at $236 million, with a stabilized cash capitalization rate of 5.3% at an initial annual rental rate of approximately $67 per square foot.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
none
-
News
Breakthrough Properties Acquires Majority Interest in Callan Ridge, A Newly-Constructed, Fully-Leased Life Science Campus in Torrey Pines
Rhea-AI Summary
Breakthrough Properties (BMY) Acquires Majority Interest in Callan Ridge, a Class A Life Science Campus in San Diego Through a Joint Venture with Healthpeak Properties (PEAK)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
acquisition
News
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
Rhea-AI Summary
Bristol Myers Squibb (BMY) announces that the European Medicines Agency (EMA) has validated its marketing authorization application for repotrectinib, a next-generation tyrosine kinase inhibitor (TKI), as a treatment for ROS1 TKI-naïve and -pretreated adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and TKI-naïve and -pretreated adult and pediatric patients 12 years and older with NTRK-positive locally advanced or metastatic solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
none
-
News
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
Rhea-AI Summary
Bristol Myers Squibb (BMY) to Acquire RayzeBio (RYZB) for $4.1 Billion, Expanding Oncology Portfolio and Radiopharmaceutical Platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
acquisition
-
News
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that its Founded Entity, Karuna Therapeutics, Inc., and Bristol Myers Squibb (NYSE: BMY) have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
News
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
Rhea-AI Summary
Bristol Myers Squibb (BMY) will acquire Karuna Therapeutics, Inc. (KRTX) for $14.0 billion, aiming to enhance their growth and diversify the portfolio in the neuroscience space. The transaction is expected to close in the first half of 2024, with KarXT, a first-in-class treatment for schizophrenia and Alzheimer's disease psychosis, as the key asset.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
-
News
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
Rhea-AI Summary
Bristol Myers Squibb (BMY) to Acquire Karuna Therapeutics, Inc. (KRTX) for $14 Billion, Expanding Its Portfolio in Neuroscience
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
-
News
Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) to Present at J.P. Morgan's 42nd Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
conferences
News
Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) to participate in 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences
Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#121 Ranked by Market Cap
#4058 Ranked by Stock Gains
#657 Ranked by Dividends

BMY Stock Data

97.81B
2.02B
0.1%
78.93%
1.73%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About BMY

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.